W. Mattsson
Impact in
- Oncology top 10%
- Cancer Treatment and Pharmacology
- Viral-associated cancers and disorders
- HER2/EGFR in Cancer Research
- Pathology and Forensic Medicine top 10%
- Lymphoma Diagnosis and Treatment
Papers in
- Oncology 22
- Cancer Treatment and Pharmacology 12
- Peptidase Inhibition and Analysis 3
W. Mattsson
27 papers receiving 396 citations
Peers
Comparison fields: 5 of 73
- Oncology 271
- Pathology and Forensic Medicine 134
- Cancer Research 60
- Neurology 60
- Reproductive Medicine 32
Countries citing papers authored by W. Mattsson
This map shows the geographic impact of W. Mattsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Mattsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Mattsson more than expected).
Fields of papers citing papers by W. Mattsson
This network shows the impact of papers produced by W. Mattsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Mattsson. The network helps show where W. Mattsson may publish in the future.
Co-authorship network
The 25 scholars most cited alongside W. Mattsson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Phase II study of weekly low-dose 4'-epi-doxorubicin in advanced postmenopausal breast cancer. | 1984 | 15 |
| 2 | 1983 | 16 | |
| 3 | 1983 | 25 | |
| 4 | A weekly schedule of low-dose doxorubicin in treatment of advanced breast cancer. | 1982 | 25 |
| 5 | Phase II study of spirogermanium in advanced ovarian malignancy. | 1981 | 18 |
| 6 | 1981 | 5 | |
| 7 | 1980 | 22 | |
| 8 | 1980 | 12 | |
| 9 | Adriamycin-methotrexate combination chemotherapy of advanced carcinoma of the cervix: a third look. | 1980 | 19 |
| 10 | Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women. | 1979 | 38 |
| 11 | 1979 | 1 | |
| 12 | 1979 | 3 | |
| 13 | Phase II study of Leo 1031 (prednimustine) in advanced ovarian carcinoma. | 1979 | 16 |
| 14 | 1979 | 98 | |
| 15 | 1978 | 3 | |
| 16 | Antineoplastic-drug effect evaluated with a new X-ray stereophotographic measurement of the tumour volume. | 1978 | 8 |
| 17 | Phase II study of combined vincristine, adriamycin, cyclophosphamide, and methotrexate with citrovorum factor factor rescue in metastatic breast cancer. | 1977 | 9 |
| 18 | 1977 | 28 | |
| 19 | 1977 | 4 | |
| 20 | 1976 | 6 |
About W. Mattsson
W. Mattsson is a scholar working on Oncology, Otorhinolaryngology, Cancer Research, Obstetrics and Gynecology and Reproductive Medicine, having authored 29 papers that have together received 474 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (12 papers), Estrogen and related hormone effects (4 papers), Breast Cancer Treatment Studies (4 papers), Chemotherapy-induced cardiotoxicity and mitigation (4 papers), Endometrial and Cervical Cancer Treatments (3 papers), Ovarian cancer diagnosis and treatment (3 papers), Peptidase Inhibition and Analysis (3 papers) and Lung Cancer Treatments and Mutations (3 papers). The work is most often cited by research in Oncology (271 citations), Pathology and Forensic Medicine (134 citations), Cancer Research (60 citations), Neurology (60 citations) and Reproductive Medicine (32 citations). W. Mattsson has collaborated with scholars based in Sweden and Denmark. Frequent co-authors include T. Landberg, Claes G. Tropé, Birger Åstedt, Torgil R. Möller, Leif Håkansson, P Westling, Bo Johansson, D. Killander, Per Lenner and S Borgström. Their work appears in journals such as Cancer, Acta Oto-Laryngologica, The Journal of Urology, Breast Cancer Research and Treatment and Tumori Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.